6 results
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
7 Sep 23
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
4:21pm
and Neurocritical Care Society. Dr. Ling is a member of the Society for Critical Care Medicine, the American Society of Pharmacology and Experimental
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
10 Nov 22
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:19pm
- Presenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
10 Aug 22
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
12:00am
at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting for the ongoing Phase 1/2a clinical trial to assess the safety and efficacy
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
16 May 22
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:47pm
to CD19 on placental CD34+derived, cryopreserved, off-the-shelf, allogeneic CYNK cells were presented at the American Society of Hematology (ASH
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
31 Mar 22
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:06pm
) adenocarcinoma.
Also in November 2021, Celularity presented preclinical data in a poster presentation at the Society of Immunotherapy Cancer (SITC) annual … EGFR+ tumors.
In December 2021, Celularity presented preclinical data for CYNK-101 at the American Society of Hematology (ASH) annual meeting
425
3t2bey dp
7 Jul 21
Business combination disclosure
4:11pm
- Prev
- 1
- Next